Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04131595 · ClinicalTrials.gov registry record · Phase 1
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
A Phase 1 study of Equine Encephalitis, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04131595 is a Phase 1 study of Equine Encephalitis that has completed, run by Bavarian Nordic. The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04131595, a Phase 1 study of Equine Encephalitis, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.
Conditions Studied
Interventions
- BIOLOGICAL MVA-BN-WEV Dose 1
- BIOLOGICAL MVA-BN-WEV Dose 2
- BIOLOGICAL MVA-BN-WEV Dose 3
Study Locations (1)
Kansas
- Johnson County Clin-Trials - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2020-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04131595
The ClinicalTrials.gov registry entry for NCT04131595 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Equine Encephalitis appearing as the primary indexed condition, and to 3 interventions - of which MVA-BN-WEV Dose 1 is the first listed.
NCT04131595 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT04131595 about?
NCT04131595 is a clinical study titled "Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects". To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.
What is the current status of trial NCT04131595?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2019-10-07. Estimated completion is 2020-07-22.
What conditions does trial NCT04131595 study?
This clinical trial studies the following conditions: Equine Encephalitis.
What interventions are being tested in trial NCT04131595?
The interventions under investigation include: MVA-BN-WEV Dose 1 (BIOLOGICAL), MVA-BN-WEV Dose 2 (BIOLOGICAL), MVA-BN-WEV Dose 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04131595?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04131595 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.